Zebinix eslicarbazepine acetate regulatory update

Dainippon disclosed in its earnings for the 6 months ended Sept. 30 that in June it submitted a regulatory application to Health Canada for eslicarbazepine as adjunctive therapy to treat epilepsy. The product is under review for the indication in the U.S., where it is known as Stedesa (see BioCentury, March 4). ...